InvestorsHub Logo
Followers 48
Posts 18364
Boards Moderated 0
Alias Born 02/26/2001

Re: pinguo77 post# 83503

Monday, 02/15/2021 11:01:03 AM

Monday, February 15, 2021 11:01:03 AM

Post# of 113765
Here it is!!
Advanomics Corporation, the Parent Company of Sunshine Biopharma, Inc., Completes Acquisition of Adva-27a Patents
Published: Nov 27, 2012


MONTREAL--(Marketwire - November 27, 2012) - Advanomics Corporation, the parent company of Sunshine Biopharma Inc. (OTCQB: SBFM), is pleased to announce that it has just completed acquisition of the worldwide patents covering Adva-27a from Institut National des Sciences Appliquees, a government research lab in France. Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells as well as other aggressive cancer cells in vitro (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). One of the patents acquired is a US patent issued only a few months ago on August 7, 2012 under US patent number 8,236,935. This together with patents previously issued in Europe as well as other patent applications currently pending elsewhere around the world broadly cover Sunshine Biopharma's flagship oncology drug candidate, Adva-27a.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SBFM News